特朗普政府正在与制药公司诺和诺德和礼来公司谈判一项协议，通过以下方式以更低的价格提供他们的一些减肥药物TrumpRx知情人士告诉ABC新闻。
根据悬而未决的协议，一个月的药物供应将花费大约149美元，并包括一些医疗保险制度受益者，一个消息来源告诉ABC新闻。
消息人士称，制药公司和政府之间的讨论仍在进行中。消息人士称，如果达成协议，预计最快将于本周宣布。
端点行业出版物《新闻》首先报道了政府即将与制药巨头达成协议。
白宫发言人没有回应置评请求。新闻秘书卡罗琳·莱维特(Karoline Leavitt)周二在一次新闻发布会上表示，她“不会在未来的任何公告上领先于总统”，但引用了特朗普“对降低美国药品价格的坚定承诺”。
今年5月，特朗普签署了一项行政命令，要求公司只向美国患者收取与其他国家相同的费用，这被称为“最惠国”定价。
诺和诺德的发言人在一份声明中告诉ABC新闻，该公司“是就最惠国行政命令与政府进行建设性的讨论。我们仍将重点放在提高患者的可及性和可负担性上，我们将继续努力寻找帮助人们获得所需药物的解决方案。"
礼来公司的一位发言人说:“礼来公司正在与政府进行讨论，以进一步扩大患者的可及性，保持创新，并促进我们药品的可负担性。我们目前没有具体的细节可以分享。”
诺和诺德生产流行的减肥药Wegovy莉莉是Zepbound的制造商。
Eli Lilly, Novo Nordisk negotiating deal with Trump administration on obesity drug prices
The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their weight loss drugs at a lower price throughTrumpRx, sources familiar with the talks told ABC News.
Under the pending agreements, a month's supply of the drugs would cost roughly $149 and be covered for someMedicarebeneficiaries, one source told ABC News.
Discussions between the pharmaceutical companies and the administration are still ongoing, the sources said.If an agreement is reached, an announcement is expected as soon as this week, according to the sources.
EndpointNews, an industry publication, first reported that the administration was nearing deals with the pharmaceutical giants.
A White House spokesperson did not respond to a request for comment. Press secretary Karoline Leavitt at a briefing Tuesday said she would "not get ahead of the president on any future announcements" but cited Trump's "strong commitment to bringing down drug prices in this country."
In May, Trump signed an executive order to pressure companies to only charge U.S. patients the same rate as they charge in other countries, which is called "most favored nation" pricing.
A spokesperson for Novo Nordisk told ABC News in a statement that the company "isengaged in constructive discussions with the administration regarding the Most Favored Nation executive order. We remain focused on improving patient access and affordability, and we will continue to work to find solutions that help people access the medication they need."
An Eli Lilly spokesperson said: "Lilly is in discussions with the administration to further expand patient access, preserve innovation, and promote affordability of our medicines. We do not have specific details to share at this time."
Novo Nordisk makes the popular weight loss drug Wegovy; Lilly is the maker of Zepbound.
